Rose McNulty

Experts discuss the urgent need for equitable access to cancer care, addressing barriers in treatment delivery and the importance of personalized medicine.

Experts discuss the intersection of innovation, affordability, and access in cancer care, focusing on multiple myeloma and NSCLC advancements.

Ritlecitinib significantly improves hair regrowth and reduces psychosocial burdens in patients with alopecia areata, enhancing emotional well-being over time.

Key factors influencing chronic urticaria duration highlight the importance of early identification and management in primary care settings.

CMS introduced the GENEROUS Model to reduce Medicaid drug costs, enhance access, and improve health outcomes for beneficiaries starting in 2026.

The White House announced significant drug pricing cuts for GLP-1s for diabetes and obesity for Medicare and Medicaid beneficiaries and on TrumpRx.

In the phase 3 BRAVE-AA-PEDS trial, baricitinib led to significant scalp, eyelash, and eyebrow hair regrowth at 1 year in adolescents with alopecia areata.

Sophia Humphreys, PharmD, MHA, BCBBS, discusses common barriers to cancer therapy and how care teams can assist patients in navigating them.

Nicoletta Colombo, MD, PhD, of the University of Milan-Bicocca, discussed the rationale behind paclitaxel with bevacizumab and pembrolizumab in ovarian cancer.

There is a significant link between chronic spontaneous urticaria and cardiovascular disease risk, highlighting the need for routine assessments.

Hair loss disorder can lead to a significant psychological and emotional burden that warrants more attention, new research suggests.

Innovative cancer therapies are transforming treatment landscapes, yet access challenges persist. Experts discuss strategies to enhance patient care and outcomes.

Explore the latest advancements in oncology, including biomarkers and targeted therapies, enhancing patient care at Tennessee Oncology and Vanderbilt-Ingram Cancer Center.

The real-world data support the long-term value of mepolizumab as an add-on maintenance therapy in severe asthma.

Chronic spontaneous urticaria (CSU) and atopic disorders seem to share an immunological basis and may significantly benefit from type 2 inflammation–targeted therapies.

Elinzanetant offers a new hormone-free solution for managing menopause-related hot flashes, targeting the root cause of vasomotor symptoms.

Belantamab mafodotin provides a community-friendly BCMA-directed therapy option for relapsed/refractory myeloma, says Hearn Jay Cho, MD, PhD.

The FDA has approved belantamab mafodotin for third-line or later multiple myeloma based on DREAMM-7 trial data.

Perioperative enfortumab vedotin plus pembrolizumab demonstrated significant results in a population that represents roughly half of all patients with MIBC, explained Christof Vulsteke, MD, PhD.

Balazs Halmos, MD, of Montefiore Albert Einstein Cancer Center, discussed the potential impact of subcutaneous amivantamab EGFR-mutated NSCLC.

Rebecca Dent, MD, MSc, of the National Cancer Center in Singapore, gives insights on the use of antibody-drug conjugates (ADCs) in early breast cancer treatment.

New KEYNOTE-B96 data add to previous results showing progression-free survival (PFS) and overall survival (OS) improvements vs placebo.

Stephen Freedland, MD, of Cedars-Sinai, discussed enzalutamide and leuprolide's potential to improve overall survival without sacrificing quality of life in prostate cancer.

Nirsevimab significantly reduced RSV hospitalizations in infants, reinforcing public health recommendations for its use during the RSV season.

An innovative artificial intelligence (AI) tool enhanced alopecia areata assessment and improved treatment adherence.

Allergen immunotherapy was associated with reduced medication use and improved asthma control for up to 9 years.

Explore the implications of the Most Favored Nation Order on US drug pricing reform and its potential impact on patient access and innovation.

Telemedicine improved the quality of life and inhaler technique among patients with advanced-stage chronic obstructive pulmonary disease (COPD).

The approval is the first in more than a decade for an idiopathic pulmonary fibrosis treatment.

The approval of remibrutinib for patients with chronic spontaneous urticaria was supported by data from the phase 3 REMIX-1 and REMIX-2 clinical trials.